Study of Pharmacokinetics and Pharmacodynamics of Artesunate in Pregnant Women in the Democratic Republic of Congo

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

December 31, 2008

Conditions
Malaria
Interventions
DRUG

Artesunate

A 200 mg dose of orally administered artesunate at the beginning of a 48-hour clinical sampling period.

Trial Locations (1)

Unknown

Kingasani Maternity Clinic, Kinshasa

All Listed Sponsors
collaborator

Global Network for Women's and Children's Health Research

OTHER

collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

Fogarty International Center of the National Institute of Health

NIH

collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

collaborator

National Institute of Dental and Craniofacial Research (NIDCR)

NIH

collaborator

National Cancer Institute (NCI)

NIH

collaborator

RTI International

OTHER

collaborator

University of North Carolina

OTHER

collaborator

Kinshasa School of Public Health

OTHER

lead

NICHD Global Network for Women's and Children's Health

NETWORK

NCT00538382 - Study of Pharmacokinetics and Pharmacodynamics of Artesunate in Pregnant Women in the Democratic Republic of Congo | Biotech Hunter | Biotech Hunter